What is NextCure?
NextCure is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel, first-in-class immunomedicines. The company's focus is on creating innovative treatments for cancer and other immune-related diseases, leveraging cutting-edge science to address unmet medical needs.
How much funding has NextCure raised?
NextCure has raised a total of $324.8M across 4 funding rounds:
Series A
$67M
Stock Offering
$86.3M
Stock Offering
$150M
Other Financing Round
$21.5M
Series A (2016): $67M with participation from Lilly Asia Ventures, Alexandria Venture Investments, Sofinnova Ventures, Canaan Partners, Pfizer Inc., and OrbiMed
Stock Issuance/Offering (2019): $86.3M, investors not publicly disclosed
Stock Issuance/Offering (2019): $150M, investors not publicly disclosed
Other Financing Round (2025): $21.5M featuring Ikarian Capital, Exome Asset Management, and Squadron Capital Management
Key Investors in NextCure
Ikarian Capital
Ikarian Capital is an investment firm that participated in NextCure's recent financing round. Their involvement suggests a focus on companies with significant growth potential in the healthcare sector.
Exome Asset Management
Exome Asset Management is an investment entity that contributed to NextCure's latest funding initiative. Their participation indicates an interest in innovative biopharmaceutical ventures.
Squadron Capital Management
Squadron Capital Management is a financial backer that has invested in NextCure's recent funding round. Their engagement points to a strategic alignment with companies developing advanced medical treatments.
What's next for NextCure?
With the recent influx of major strategic investment, NextCure is poised for accelerated growth and the advancement of its therapeutic pipeline. This substantial capital infusion is expected to fuel further research and development, potentially enabling the company to expand its clinical trials, enhance its discovery platforms, and solidify its market position in the competitive biopharmaceutical landscape. The enterprise-level backing suggests a strong confidence from investors in NextCure's long-term vision and its potential to deliver impactful immunomedicines.
See full NextCure company page
